The company must continuously innovate to stay ahead of competitors ... the rapid evolution of tax regulations across different jurisdictions. Vertex must ensure its software remains up-to-date ...

The company must continuously innovate to stay ahead of competitors who may offer similar tax automation solutions. Another challenge lies in the rapid evolution of tax regulations across different ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may ...

As Chief Technology Officer, Sal leads the company’s technology strategy, software engineering and innovation roadmap to ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...